Hashim Kazmi, MD
Nephrology · Bakersfield, CANPI 1538270038
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,397 of the $99,020 with a category attached, or 85.2%. 26 manufacturers reported payments, led by Amgen at 41.6% of the total. Reporting peaked in 2022 at $36,490 and has fallen 97.9% since, to $773 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 394 payments — averaging $251.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$41K
- Bayer$33K
- Fresenius USA Marketing, Inc.$16K
- Vifor Pharma, Inc.$6K
- AstraZeneca$778
- GSK$629
- plus $2K from 20 others
Across 1 payment — averaging $2605.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$3K
What the payments were for
- Speaking & faculty fees$84,39785%
- Travel & lodging$5,2965%
- Food & beverage$9,1259%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 116 | $41,143 |
| Bayer | 53 | $32,590 |
| Fresenius USA Marketing, Inc. | 63 | $15,923 |
| Vifor Pharma, Inc. | 15 | $5,506 |
| AstraZeneca(2 entities) | 25 | $778 |
| GSK | 25 | $629 |
| Ardelyx, Inc. | 12 | $357 |
| ANI Pharmaceuticals, Inc. | 16 | $297 |
| Mallinckrodt Hospital Products Inc. | 6 | $270 |
| Aurinia Pharma U.S., Inc. | 11 | $255 |
| Calliditas Therapeutics US Inc. | 6 | $196 |
| Travere Therapeutics, Inc. | 7 | $173 |
| Otsuka America Pharmaceutical, Inc. | 9 | $170 |
| Daiichi Sankyo Inc. | 7 | $135 |
| OPKO Pharmaceuticals, LLC | 6 | $112 |
| Sanofi | 1 | $102 |
| Mallinckrodt Enterprises LLC | 3 | $65 |
| Outset Medical Inc | 1 | $61 |
| Akebia Therapeutics Inc | 3 | $57 |
| Kyowa Kirin, Inc. | 2 | $56 |
| Boehringer Ingelheim | 2 | $42 |
| Baxter Healthcare | 1 | $25 |
| Novo Nordisk | 1 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Pfizer | 1 | $18 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,020 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 23 | $77,358 |
| KerendiaFinerenone | 99 | $77,313 |
| VeltassaPatiromer Calcium Sorbitex | 47 | $49,443 |
| FarxigaDapagliflozin Propanediol | 64 | $38,474 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $24,135 |
| RayaldeeCalcifediol | 12 | $20,483 |
| Sevelamer Carbonate | 36 | $6,296 |
| Calcium Acetate | 31 | $2,776 |
| Mycophenolate Mofetil | 14 | $2,527 |
| Fluconazole | 20 | $2,488 |
| ProsolParenteral Amino Acid 20% No.1 | 26 | $2,337 |
| Tacrolimus | 19 | $1,662 |
| Calcitriol | 102 | $1,068 |
| Nifedipine ErNifedipine | 16 | $807 |
| Allopurinol | 129 | $755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $15,923 | $77,35823 claims |
| BayerKerendia | $32,590 | $77,31399 claims |
| AstraZenecaFarxiga, Lokelma | $778 | $62,61091 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $112 | $20,48312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Bakersfield
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.